XyloCor
is a Pennsylvania-based biopharmaceutical company that develops and commercializes gene therapies for the treatment of cardiovascular diseases... Read moreXyloCor
is a Pennsylvania-based biopharmaceutical company that develops and commercializes gene therapies for the treatment of cardiovascular diseases... Read more
News
Mar 05, 2026
Contract Pharma
XyloCor: XyloCor Therapeutics Names New President and CEO
Mar 05, 2026
Yahoo
XyloCor: XyloCor Appoints John Tucker as President and Chief Executive Officer
Jul 11, 2025
Clinical Trials Arena
XyloCor: XyloCor doses first subject in Phase IIb trial of gene therapy candidate XC001
Jan 07, 2025
The Business Journals: Philadelphia
XyloCor: KOP firm raises $67.5M to advance gene therapy targeting multibillion-dollar opportunity
Jul 11, 2024
Clinical Trials Arena
XyloCor: XyloCor taps SmartWise's infusion device for gene therapy administration
Aug 24, 2023
Acrofan
XyloCor: XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Cardiology (ESC) Congress 2023
Aug 03, 2023
Business Wire
Press Release: XyloCor : Results from XyloCor Therapeutics' Phase 1 Portion of EXACT Trial of XC001 for Cardiovascular Disease Published in Circulation: Cardiovascular Interventions
Jan 27, 2023
Clinical Trials Arena
XyloCor: XyloCor reports positive data from refractory angina gene therapy trial
Jan 26, 2023
Endpoints News
XyloCor: XyloCor wraps up PhII for heart disease gene therapy, plans for pivotal trial
Jun 28, 2022
Business Wire
Press Release: XyloCor : XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease
XyloCor Competitors
1
2
3
4
5
6
7
8
9
10